牛牛AI助理已提取核心訊息
On December 31, 2023, T2 Biosystems, Inc., a medical device company, was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission. The filing was an amendment indicating changes in the ownership of the company's common stock. The reporting entities and individuals, collectively referred to as the Reporting Persons, include Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton, a U.S. citizen. Each of the Reporting Persons has reported beneficial ownership of 20,370 warrants to purchase T2 Biosystems' common stock, which represents 0.5% of the company's class of securities. The warrants provide the Reporting Persons with sole voting and dispositive power over the shares they could acquire. The principal business office for all Reporting Persons is located at 444 Madison Ave, Floor 41, New York, NY 10022. The filing, dated February 13, 2024, also includes a certification that the securities were not acquired for the purpose of changing or influencing the control of T2 Biosystems and were not held in connection with any transaction having such purpose or effect.
On December 31, 2023, T2 Biosystems, Inc., a medical device company, was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission. The filing was an amendment indicating changes in the ownership of the company's common stock. The reporting entities and individuals, collectively referred to as the Reporting Persons, include Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton, a U.S. citizen. Each of the Reporting Persons has reported beneficial ownership of 20,370 warrants to purchase T2 Biosystems' common stock, which represents 0.5% of the company's class of securities. The warrants provide the Reporting Persons with sole voting and dispositive power over the shares they could acquire. The principal business office for all Reporting Persons is located at 444 Madison Ave, Floor 41, New York, NY 10022. The filing, dated February 13, 2024, also includes a certification that the securities were not acquired for the purpose of changing or influencing the control of T2 Biosystems and were not held in connection with any transaction having such purpose or effect.
2023年12月31日，醫療器械公司T2 Biosystems, Inc. 成爲向美國證券交易委員會提交的附表13G文件的主體。該文件是一項修正案，表明公司普通股的所有權發生了變化。申報實體和個人，統稱爲申報人，包括Lind Global Fund II LP、Lind Global Partners II LLC和美國公民傑夫·伊斯頓。每位申報人均報告了20,370份購買T2 Biosystems普通股的認股權證的實益所有權，佔公司證券類別的0.5％。認股權證爲申報人提供了對他們可能收購的股份的唯一投票權和處置權。所有舉報人的主要業務辦公室位於紐約麥迪遜大道444號41樓，郵編10022。該文件日期爲2024年2月13日，其中還包括一份證明，證明收購這些證券不是爲了改變或影響T2 Biosystems的控制權，也不是與任何具有此類目的或效果的交易有關而持有的。
2023年12月31日，醫療器械公司T2 Biosystems, Inc. 成爲向美國證券交易委員會提交的附表13G文件的主體。該文件是一項修正案，表明公司普通股的所有權發生了變化。申報實體和個人，統稱爲申報人，包括Lind Global Fund II LP、Lind Global Partners II LLC和美國公民傑夫·伊斯頓。每位申報人均報告了20,370份購買T2 Biosystems普通股的認股權證的實益所有權，佔公司證券類別的0.5％。認股權證爲申報人提供了對他們可能收購的股份的唯一投票權和處置權。所有舉報人的主要業務辦公室位於紐約麥迪遜大道444號41樓，郵編10022。該文件日期爲2024年2月13日，其中還包括一份證明，證明收購這些證券不是爲了改變或影響T2 Biosystems的控制權，也不是與任何具有此類目的或效果的交易有關而持有的。
有用
沒用